Myles D. Greenberg, M.D.

Myles D. Greenberg, M.D.

President & Chief Executive Officer

Dr. Myles Greenberg comes to Alucent Biomedical with more than 20 years of experience in growing healthcare, medical technology and life sciences firms as an entrepreneur, operating executive, board member, clinician and investor.  Prior to joining Alucent, he served as chief development officer at IntegraMed America, a private equity backed healthcare services firm. Previously, Dr. Greenberg spent most of his career as an early-stage venture capital investor with CHL Medical Partners, HealthInvest Equity Partners and Pappas Ventures.  As a start-up venture investor and board member, he often served as lead director or in an interim management role at many dynamic companies in the biotechnology, medical device, and healthcare services sectors, such as Angiomics (acquired by PDL BioPharma), Flowcardia (acquired by CR Bard), Liposcience (acquired by LabCorp), Millennium Pharmacy Systems (acquired by PharMerica), Oriel Therapeutics (acquired by Novartis / Sandoz), NuVasive (Nasdaq: NUVA), Syntonix Pharmaceuticals (acquired by Biogen Idec), and Vascular Pathways (acquired by CR Bard).  In addition to leading the Alucent team, Dr. Greenberg currently serves on the board of directors of Urgent Care Centers of New England (d/b/a CareWell Urgent Care), a company he co-founded, and as Entrepreneur-In-Residence at the University of Utah Center for Medical Innovation. Dr. Greenberg began his career as a faculty physician and hospital administrator at Beth Israel Deaconess Medical Center / Harvard Medical School in Boston.  He holds a Master of Business Administration from Harvard Business School, Doctor of Medicine from Yale University School of Medicine and a Bachelor of Applied Science from the University of Pennsylvania School of Engineering and Applied Science and is a Diplomate of the American Board of Emergency Medicine.